Jayastu Senapati
@jayastumd
Asst. Professor, Dept. of Leukemia,
MD Anderson Cancer Center Houston
(CMC Vellore & AIIMS ND alumnus). Tweets are my own.
Vasudhaiva Kutumbakam ๐ฎ๐ณ๐๐บ๐ธ
ID: 1974184626
https://faculty.mdanderson.org/profiles/jayastu_senapati.html 20-10-2013 07:28:43
1,1K Tweet
2,2K Followers
577 Following
โก๏ธ Check out our paper just published in Blood Cancer Journal on risk factors for InO induced SOS and utlility of baseline liver elastography on subsequent InO liver tox in adults with Bcell-ALL ๐งฌ๐ฉธ Hagop Kantarjian,MD MD Anderson Cancer Center nature.com/articles/s4140โฆ
Happy Friday from MD Anderson Cancer Center ! #leusm #endcancer | Naveen Pemmaraju, MD Jayastu Senapati Naval Daver, M.D.
CMC doctors and staff join all-India IMA protest demanding #justice and increased protection for #doctors across the country. @ Sathuvachari #Vellore this morning. #KolkataDoctor #ViolenceAgainstWomen Indian Medical Association
Read our Oct 1 issue! ๐ acsjournals.onlinelibrary.wiley.com/toc/10970142/2โฆ โ Targeted lung therapy advs by Makarem & Jรคnne of Dana-Farber โ Out-of-pocket costs after #ProstateCancer screening by Anca Tilea et al โ Jayastu Senapati & Tapan Kadia et al on post SCT outcomes in older pats w/ AML OncoAlert
Thanks for sharing Naval Daver, M.D. MD Anderson Cancer Center #soho
๐ Happy to get the Second Place Poster Session Award at #SOHO2024 on โก๏ธ Venetoclax added to HyperCVAD-Nel-PegAsp In T-cell ALL/LBL: Phase 2 study MD Anderson Cancer Center Hagop Kantarjian,MD G Garcia-Manero
#SOHO2024 Presenting Princess Margaret Cancer Centre experience of using Gilt- combinations in R/R FLT3 AML. In this non-randomized study we provide enough evidence to suggest Gilteritinib combinations is a better bridge to ASCT than monotherapy AML Hub Mithun Abraham Prakash Jayastu Senapati Society of Hematologic Oncology (SOHO)